Cargando…

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy

BACKGROUND: The results of leflunomide (LEF) in patients with IgA nephropathy (IgAN) were inconsistent. METHODS: A total of 149 kidney biopsy-confirmed IgAN patients with an estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m(2) and protein excretion levels ≥0.75 g/d were enrolled, with 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yebei, Xiong, Yi, Huang, Tianlun, Liu, Xin, Xu, Gaosi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567572/ https://www.ncbi.nlm.nih.gov/pubmed/34736419 http://dx.doi.org/10.1186/s12882-021-02555-z

Ejemplares similares

The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy
por: Wang, Li, et al.
Publicado: (2019)

Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy
por: Min, Lulin, et al.
Publicado: (2017)

Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials
por: Lv, Guangxin, et al.
Publicado: (2022)

Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial
por: Ni, Zhaohui, et al.
Publicado: (2021)

A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study
por: Chen, Shasha, et al.
Publicado: (2018)

An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
por: Huang, Xin, et al.
Publicado: (2021)

Leflunomide therapy for IgA vasculitis with nephritis in children
por: Hou, Ling, et al.
Publicado: (2021)

Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy
por: Wang, Yu, et al.
Publicado: (2023)

New-onset IgA nephropathy following COVID-19 vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis
por: Liu, Yiwen, et al.
Publicado: (2023)

Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison
por: Ismail, Gener, et al.
Publicado: (2020)

Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy
por: Shang, Shunlai, et al.
Publicado: (2022)

Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
por: Pozzi, Claudio, et al.
Publicado: (2012)

Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)

The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
por: Liang, Mengjun, et al.
Publicado: (2022)

Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy
por: Sarcina, Cristina, et al.
Publicado: (2016)

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
por: Cai, Qingqing, et al.
Publicado: (2017)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

The response of the Oxford classification to steroid in IgA nephropathy: a systematic review and meta-analysis
por: Yang, Pingping, et al.
Publicado: (2017)

Significance of Urinary Full-Length Megalin in Patients with IgA Nephropathy
por: Seki, Takuto, et al.
Publicado: (2014)

Validation of the revised Oxford classification for IgA nephropathy considering treatment with corticosteroids/immunosuppressors
por: Moriyama, Takahito, et al.
Publicado: (2020)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment
por: Feng, Qipu, et al.
Publicado: (2022)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
por: Yang, Byeong Yun, et al.
Publicado: (2012)

An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
por: Okada, Mari, et al.
Publicado: (2022)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria
por: Pei, Gaiqin, et al.
Publicado: (2020)

Albumin-to-fibrinogen ratio is an independent predictor of corticosteroid response and prognosis in patients with IgA nephropathy
por: Zhang, Yu, et al.
Publicado: (2023)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine
por: Niel, Olivier, et al.
Publicado: (2021)

Efficacy and safety of Telitacicept in patients with IgA nephropathy
por: Liang, Dongrui, et al.
Publicado: (2023)

Thrombotic Microangiopathy in IgA Nephropathy
por: Nasri, Hamid
Publicado: (2013)

Role of complement in IgA nephropathy
por: Daha, Mohamed R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sfrtsdqu58kulm22k91lsbqdji